Aberrations of the Wnt canonical pathway (WCP) are known to contribute to the pathogenesis of various types of cancer. We hypothesize that these defects may exist in mantle cell lymphoma (MCL). Both the upstream and downstream aspects of WCP were examined in MCL cell lines and tumors. Using WCPspecific oligonucleotide arrays, we found that MCL highly and consistently expressed Wnt3 and Wnt10. 
ABSTRACT
Aberrations of the Wnt canonical pathway (WCP) are known to contribute to the pathogenesis of various types of cancer. We hypothesize that these defects may exist in mantle cell lymphoma (MCL). Both the upstream and downstream aspects of WCP were examined in MCL cell lines and tumors. Using WCPspecific oligonucleotide arrays, we found that MCL highly and consistently expressed Wnt3 and Wnt10. For personal use only. on October 28, 2017 . by guest www.bloodjournal.org From
INTRODUCTION
Mantle cell lymphoma is a specific type of non-Hodgkin's B-cell lymphoma recognized by the World Health Organization Classification Scheme (1) . The genetic hallmark of this disease is the recurrent chromosomal abnormality, the t(11;14)(q13;q32), which brings the cyclin D1 gene under the influence of the enhancer of the immunoglobulin heavy chain (IgH) gene, leading to cyclin D1 overexpression (2) . While cyclin D1 overexpression is likely to be pathogenetically important in MCL, evidence suggests that additional biochemical defects are necessary for lymphomagenesis. For instance, using Eµ-cyclin D1 transgenic mice, two research groups have previously shown that enforced cyclin D1 expression in B-cells is not sufficient to induce tumor formation (3, 4) . Furthermore, large-scale cDNA microarray studies using frozen MCL tumors have revealed a relatively large number of biochemical abnormalities in MCL, with these defects frequently implicated in the regulation of apoptosis, cell cycle progression and DNA repair (5) (6) (7) (8) (9) (10) . Examination of specific cellular signaling pathways also provided additional insights into the biology of these tumors. For instance, a relatively recent study reported constitutive activation of the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway in a subset of MCL tumors, particularly those with a blastoid morphology (11) .
The Wnt canonical pathway (WCP) is important for normal cell growth and development (12, 13) . Defects of this pathway have been shown to play roles in the pathogenesis of a variety of human cancers, particularly those of epithelial For personal use only. on October 28, 2017 . by guest www.bloodjournal.org From type (14) . Normally, WCP is activated via ligation of the Wnt proteins, which are secreted glycoproteins, to their respective dimeric cell surface receptors composed of the frizzled proteins and the low density lipoprotein-receptor related proteins (LRP) (15) . The binding of the Wnt proteins to their receptors is negatively regulated by the Wnt inhibitory factor and the sFRP proteins (sFRP1-5). Upon ligation to their receptors, the dishevelled proteins (DvL's), a family of the upstream WCP signaling proteins, are phosphorylated (16, 17) . In WCP, Wnt stimulation results in inactivation/phosphorylation of GSK3β, as well as the dissociation of the 'destruction complex'. The normal function of the destruction complex, composed of several proteins including axin, adenomatous polyposis coli and GSK3β, has been recognized as a crucial regulator of a wide range of cellular functions including apoptosis and cell proliferation. One of the known biological functions of this complex is to inhibit β -catenin, by sequestration and promotion of its proteasome degradation (12) . With GSK3β inactivation and dissociation of the destruction complex, β -catenin is released and allowed to accumulate in the cell and translocate to the nucleus, where it upregulates the transcription of multiple genes including cyclin D1. WCP is particularly interesting in the context of MCL, in view of its regulatory role on cyclin D1 expression.
The status of WCP has not been comprehensively studied in MCL. Specifically, the expression profile of various Wnt proteins and their receptors, as well as the activation/phosphorylation status of GSK3β and the DvL protein, are not known.
In light of the biological significance of WCP in normal and cancer cells, we For personal use only. on October 28, 2017 . by guest www.bloodjournal.org From attempted to determine if defects in WCP may exist in MCL, and whether these defects may contribute to the pathogenesis of these tumors.
MATERIALS AND METHODS

1) MCL cell lines and primary tumors
The characteristics of the three MCL cell lines, Jeko-1, Mino and SP53, have been previously described (18) . Briefly, these 3 cell lines have the mature B-cell immunophenotype, carry the t(11;14)(q13;q32), and express cyclin D1. All 3 cell lines are negative for the Epstein-Barr virus nuclear antigen. All MCL primary tumors were diagnosed at the Cross Cancer Institute and the diagnostic criteria were based on those described in the World Health Organization Classification Scheme(1). Five of the 64 MCL tumors used in this study were of the blastoid variant. All cases were confirmed to express cyclin D1 by immunohistochemistry.
The use of these tissues has been approved by University of Alberta Cancer Board Institutional Ethics Committee.
2) Reagents
Quercetin, a β -catenin inhibitor, was purchased from Sigma-Aldrich (St. Louis, MO, USA). Stock solutions were prepared by dissolving in dimethyl sulfoxide (DMSO)(Sigma-Aldrich, St. Louis, MO, USA) following the manufacturer's instruction. Addition of DMSO without quercetin served as the negative controls.
3) Subcellular protein fractionation, Western blots and antibodies
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For subcellular protein fractionation, we employed a kit purchased from Active Motif (Carlsbad, CA, USA) and followed the manufacturer's instructions.
Preparation of cell lysates for Western blots is described as follows: cells were washed with phosphate-buffered saline (PBS), and cellular proteins were precipitated with ice-cold 5% trichloroacetic acid (TCA) overnight at 4 
4) Immunofluorescence and confocal microscopy
Cells were grown on coverslip previously treated with poly-L-lysine (SigmaAldrich) in a 6-well plate and fixed with 3% paraformaldehyde in PBS (pH 7.4). values, which were defined as the fractional cycle number at which the fluorescence passes an arbitrarily set threshold, were analysed using the SDS (version 2.2.2) program (Applied Biosystems). The CT value of each gene was normalized to that of GAPDH, which is included in this commercially available kit.
7) MTS assay and cell viability
MCL cells lines in RPMI 1640 were seeded at 20,000 cells/well in a 96-well plate and the assay was conducted following the manufacturer's instructions (Promega, Nepean, Ontario, Canada). The measurements were obtained at a wavelength of 450 nM using a Biorad Microplate Reader. The absorbance values were normalized to the untreated cells using the microplate Manager 5.2.1 software (Biorad). All experiments were performed in triplicates. Cell viability was determined were by the trypan blue exclusion test.
8) Immunohistochemistry
Immunohistochemistry was performed using standard techniques as previously described (20) . Briefly, formalin-fixed, paraffin-embedded tissue sections of 4 μ M thickness were deparafinized and hydrated. Heat-induced epitope retrieval was performed using citrate buffer (pH=6) and a microwave histoprocessor (RHS, Milestone, Bergamo, Italy). Tissue sections were then incubated with anti-p-GSK3β (1:500) or anti-β-catenin (1:1200) overnight in a humidified chamber at 4˚C. All of these primary antibodies were the same as those used 
10) Recombinant sFRP
Human sFRP1 (catalog number, 1384-SF) and sFRP4 (catalog number, 1827-SF) were purchased from R&D systems (Minneapolis, MN, USA). Human recombinant sFRP2 and sFRP3 are not commercially available. Jeko-1 and SP53 cells were treated with or without sFRPs proteins in a serum-free medium.
After 3 hours of treatment, the cells were lysed and analyzed by Western blot.
11) Assessment of cyclin D1 expression using quantitative RT-PCR
The expression of cyclin D1 in MCL cells treated with quercetin was assessed using an quantitative RT-PCR (qRT-PCR) assay adapted from a previously published method (21) . The assay was performed using the Applied Biosystems 7900 HT, and the EXPRESS SYBR® GreenER™ qPCR SuperMixes and a twostep qRT-PCR kit from Invitrogen were employed. Triplicate experiments were performed and the statistical significance of the differences is assessed using Student t-test.
12) Cell-cycle analysis by flow cytometry
Cells were synchronized by serum starvation for 24 hours. Subsequently, cells at a concentration of 1 x 10 6 cells/mL were re-suspended in DMEM with 10% FBS.
To prepare cells for cell cycle analysis, cells were washed twice with PBS and fixed with 70% cold ethanol for 2 hours. After washes with PBS, cells were treated with RNase (1 mg/mL) at 37°C for 30 minutes. Cells were then washed 3 times with PBS and staining was achieved by incubating cells with 100 μ g/ml propidium iodide containing 0.1% Triton X-100. Cells were analyzed on a FACS Calibur (Becton-Dickinson, San Jose, CA, USA).
13) Statistical analysis
Data are expressed as mean +/-standard derivation. Statistical significance was tested using Student's t-test and statistical significance was achieved when the p value is <0.05.
RESULTS
Nuclear localization and transcriptional activity of β -catenin in MCL cells
We first assessed the activity of β -catenin, the downstream effectors of WCP, in degradation (22) . This finding suggests that the negative regulatory mechanism for β -catenin, which is known to promote its proteosome degradation, is at least partially functional in these cells.
The Similarly, we surveyed the expression of p-GSK3β using a monoclonal antibody and immunohistochemistry. p-GSK3β was detectable in 36 (56%) cases.
Importantly, the expression of these two markers significantly correlated with Figure 2 . In the positive cases, β -catenin staining was mostly nuclear, although a weak cytoplasmic staining was often detectable. In β -catenin-negative cases, we were able to consistently identify relatively weak cytoplasmic staining. The staining for pGSK-3β was cytoplasmic in the positive cases. Tonsils were included as the negative controls; both nuclear β -catenin and p-GSK3β were not detectable using our immunohistochemical methods.
Status of the upstream WCP in MCL cells
We comprehensively surveyed the expression of various Wnt-related genes using Wnt pathway-specific oligonucleotide arrays. All of the results were normalized to the housekeeping genes included in this assay kit. As summarized in Table 1 
To further evaluate whether Wnt stimulation indeed occurs in MCL, we assessed the phosphorylation status of the DvL proteins as a surrogate marker. In the three MCL cell lines and 5 frozen MCL tumors used to assess the expression of p-GSK3β in this study, we clearly identified the presence of the slow migrating/phosphorylated species of DvL-2 ( Figure 3 ). Mouse stem cell lysates, which are known to contain the phosphorylated forms of DvL-2, were used as a positive control (17, 23 ). Interestingly, the expression level of DvL-2 correlated with that of p-GSK3β expression, as tumor P2 and P3 (with no or weak expression of p-GSK3β) had relatively low levels of DvL-2 ( Figure 3B ). Results for DvL-3 followed the same pattern as those for DvL-2. DvL-1 was not detectable in all MCL cell lines and tumors examined.
Blockade of the upstream WCP led to decreased p-GSK3β
To determine if GSK3β phophorylation/inactivation is directly linked to Wnt activation, we added soluble recombinant sFRP1 or 4 (naturally-occurring decoys of the Wnt receptors) (24) to the three MCL cell lines. Using quantitative RT-PCR, we have previously determined that these 2 factors were not produced or produced at a low level in these three MCL cell lines (unpublished data). As shown in Figure 4A , sFRP1 induced a statistically significant and dosedependent decrease in the p-GSK3β levels for both Jeko-1 and SP53 cells. The decrease in p-GSK3β in both cell lines was approximately 50%. Significant differences were also observed when sFRP4 were used, with approximately 60% reduction in the level of pGSK-3β in both cell lines. These findings support the For personal use only. on October 28, 2017. by guest www.bloodjournal.org From concept that phosphorylation and inactivation of GSK3β can be directly attributed to WCP.
Blockade of WCP resulted in a significant reduction in cell growth
To test if activation of WCP is biological significant in MCL, we assessed if cell growth is altered after the WCP is blocked by either siRNA knock-down of DvL-2 or using quercetin, a pharmacologic agent reported to be relatively specific for β -catenin (25, 26) . The choice of DvL-2 (instead of DvL-3) is based on our finding that the phosphorylated form of DvL-2 is more strongly expressed than that of DvL-3. As shown in figure 5A , transfection of siRNA results in a concentrationdependent reduction in the expression of DvL-2 detectable by Western blots.
Correlating with the downregulation of DvL-2, there was a significant reduction in proliferation at 48 hours, as assessed by the MTS assay ( Figure 5B) . A substantial degree of cell proliferation was evident even after treatment with DvL-2 siRNA, and we believe this is due to that fact that the DvL-2 inhibition was far from being complete, and that other mechanisms (such as the Akt signaling pathway) likely continue to promote cell growth. With the same experimental conditions, we detected the occurrence of apoptosis, as evidenced the dosedependent increase in cleaved caspase 3 in the treated cells but not the negative control cells ( Figure 5C ). Similarly, as illustrated in Figure 6A Figure 6C and support that the mechanism underlying the quercetin-induced decrease in cyclin D1 is transcriptional.
To further characterize the apoptosis induced by WCP inhibition, we assessed the expression of two anti-apoptotic proteins including Bcl-XL and Bcl-2. As shown in Figure 6D , these two anti-apoptotic proteins were down-regulated in For personal use only. on October 28, 2017. by guest www.bloodjournal.org From MCL cells treated with quercetin. As shown in Figure 6E , the occurrence of apoptosis induced by quercetin involved cleavages of PARP, caspase 3, caspase 7 and caspase 9. The occurrence of apoptosis in quercetin-treated MCL cells was also further supported by morphologic examination (not shown).
Since quercetin was also reported to be an inhibitor of the PI3K/Akt pathway, which is also a known regulator of GSK3β, we assessed if the quercetin effects on MCL are mediated via PI3K/Akt or directly on β -catenin. As shown in Figure 7 , no detectable change was seen in the expression levels of p-GSK3β. Thus, these findings support that the observed biological effects are directly mediated upon β -catenin.
DISCUSSION
WCP is involved in the transduction of various extracellular stimuli that regulate a wide range of fundamental cellular processes including cell proliferation and apoptosis (14) . The oncogenic potential of WCP has been illustrated in a number of human cancer, most notably those of epithelial cancers (14) . The importance of WCP in hematopoietic malignancies is not as extensively studied. More recently, β -catenin activation, coupled with GSK3β inactivation, has been demonstrated in chronic myeloid leukemia in blast crisis and precursor B-cell acute lymphoblastic leukemia (27) . With regard to the mechanism of GSK3β inactivation and phosphorylation, it has been recently suggested that the PI3K/Akt signaling pathway may play a role.
Multiple publications have reported Akt activation in MCL, particularly those of the blastoid variant (11) . In one study, GSK3β was examined in 3 typical MCL cases; 2 of these 3 cases are strongly positive, even in the absence of detectable pAkt (11) . These findings support the concept that Akt is likely not the only means by which GSK3β is inactivated in MCL. Our results from this study suggest that WCP may well be the alterative mechanism by which GSK3β is inactivated. Correlating with this concept, WCP has been reported to induce phosphorylation GSK3β independent of PI3K/Akt in other cell types (28) (29) (30) (31) (32) .
To support that WCP stimulation directly contributes to GSK3β inactivation in MCL, we assessed the effects on GSK3β after WCP is inhibited by using sFRP's (naturally-occurring decoys for the Wnt receptors). The use of sFRP's and their inhibitory effects on the phosphorylation/activation status of GSK3β has previously described in other biological systems (24, 28, (33) (34) (35) . In MCL, blockade of WCP by sFRP1 or sFPR4 resulted in a significant decrease in p-GSK3β. This observation is consistent with some of the published results generated in different cell types and experimental systems (34) (35) (36) . These findings strongly support that the phosphorylation/inactivation of GSK3β is directly attributed to WCP stimulation. Our studies using siRNA to inhibit DvL-2 revealed results that are consistent with this concept. Specifically, downregulation of DvL-2 triggered apoptosis and led to a significant reduction in cell proliferation ( Figure 5 ).
Our oligonucleotide microarray data generated using (Table 1) .
In this study, we have provided the first evidence that β -catenin is biologically significant in MCL, as blockade of WCP using quercetin or siRNA knockdown of DvL-2 decreased cell growth. Our results are consistent with those described in other experimental model; degradation of DvL-2 has been shown to block WCP (42) . In the quercetin experiments, apoptosis was triggered, with involvement of activation of caspase 3, 7 and 9. Quercetin has been reported to be a potent (25, 26) . Nevertheless, it has also been reported to be an inhibitor of the PI3K/Akt pathway (43) . The lack of detectable change in the levels of p-GSK3β or pAkt after quercetin treatment supports the concept that the quercetin effects in MCL cells were not dependent on PI3K/Akt or GSK3β. Instead, we believe that the quercetin effects are via direct β -catenin inactivation, as previously described in other models (26) . In For personal use only. on October 28, 2017. by guest www.bloodjournal.org From
